How does dupixent's 2020 revenue compare to other drugs in its class?

In 2020, Dupixent (dupilumab) generated roughly $4 billion in global net sales. That made it the leading drug in its class—IL-4/IL-13 pathway inhibitors—for inflammatory diseases, with no other approved drugs in that exact mechanism achieving comparable sales at the time. Other IL-4/IL-13–targeting agents (like Lebrikizumab or Tralokinumab) were still in development or early in rollout and did not have meaningful revenue in 2020.

If you’d like, I can pull exact figures from Regeneron/Sanofi’s 2020 annual/quarterly reports and show the per-indication breakdown and regional sales.